» Articles » PMID: 29156687

Distribution of Lymph Node Metastasis from Lymphoepithelial-like Carcinoma of the Parotid

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Nov 22
PMID 29156687
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To explore the distribution of node spread from lymphoepithelial-like carcinoma (LELC) of the parotid gland based on the 2013 updated guidelines for neck node levels.

Results: 42 (58.3%) cases had metastatic nodes, all were localized at the ipsilateral neck. The detailed distribution was: level Ia 0, level Ib 6(14.3%), level II 34 (80.1%), level III 16 (38.1%), level IV 9 (21.4%), level V 7 (16.7%), level VI 0, level VII 0, level VIII 37 (88.1%), level IX 0, level Xa 2 (4.8%), and level Xb 0. Lymphadenopathy in level Ib, V and Xa was always accompanied with level II or level VIII nodal metastasis. No statistical significance was found in the incidence of nodal involvement between T1-2 and T3-4 tumors (57.4% versus 61.1%, = 0.78).

Methods: We retrospectively reviewed the surgical and imaging documents of 72 cases of LELC from the parotid gland between January 2004 and November 2015. All patients received contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI). Parotid metastasis from nasopharyngeal cancer (NPC) was excluded. Nodal status and distribution was evaluated by both pathologic reports and imaging studies.

Conclusions: This is the first description of topography of cervical nodal metastases from LELC of the parotid gland. Incidence of nodal involvement is high. Nodes at ipsilateral level VIII and II were most frequently involved, followed by level III, IV, V and Ib. Nodes in level Ia, VI and level VII were rarely seen.

Citing Articles

Lymphoepithelial carcinoma of the parotid gland.

Kallel S, Ayadi S, Salem N, Zghal M, Mariem B, Ayedi L SAGE Open Med Case Rep. 2024; 12:2050313X241260210.

PMID: 38868663 PMC: 11168047. DOI: 10.1177/2050313X241260210.


Is radical radiotherapy with/without surgery an effective treatment in the lymphoepithelial carcinoma of the salivary gland?.

Niu X, Liu P, Wang X, Hu C BMC Cancer. 2023; 23(1):968.

PMID: 37828474 PMC: 10568878. DOI: 10.1186/s12885-023-11466-1.

References
1.
Saku T, Cheng J, Jen K, Tokunaga M, Li J, Zhang W . Epstein-Barr virus infected lymphoepithelial carcinomas of the salivary gland in the Russia-Asia area: a clinicopathologic study of 160 cases. Arkh Patol. 2004; 65(2):35-9. View

2.
Lam W, Chan Y, Leung S, Metreweli C . Retropharyngeal lymphadenopathy in nasopharyngeal carcinoma. Head Neck. 1997; 19(3):176-81. DOI: 10.1002/(sici)1097-0347(199705)19:3<176::aid-hed2>3.0.co;2-#. View

3.
Borg M, Benjamin C, Morton R, Llewellyn H . Malignant lympho-epithelial lesion of the salivary gland: a case report and review of the literature. Australas Radiol. 1993; 37(3):288-91. DOI: 10.1111/j.1440-1673.1993.tb00079.x. View

4.
Li F, Zhu G, Wang Y, Wang Y, Chen T, Ji Q . A clinical analysis of 37 cases with lymphoepithelial carcinoma of the major salivary gland treated by surgical resection and postoperative radiotherapy: a single institution study. Med Oncol. 2014; 31(5):957. DOI: 10.1007/s12032-014-0957-9. View

5.
Schneider M, Rizzardi C . Lymphoepithelial carcinoma of the parotid glands and its relationship with benign lymphoepithelial lesions. Arch Pathol Lab Med. 2008; 132(2):278-82. DOI: 10.5858/2008-132-278-LCOTPG. View